Literature DB >> 31797346

Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.

Patrick Brown1, Gerhard Zugmaier2, Lia Gore3, Catherine A Tuglus4, Arend von Stackelberg5.   

Abstract

Year:  2019        PMID： 31797346     DOI： 10.1111/bjh.16306

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  1 in total

1.  Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.

Authors:  Cristina F Contreras; Christine S Higham; Astrid Behnert; Kailyn Kim; Elliot Stieglitz; Sarah K Tasian
Journal:  Pediatr Blood Cancer       Date:  2020-10-24       Impact factor: 3.167
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.